10 patients will be enrolled in the initial cohort and will receive two infusions of
unlabeled huJ591 on days 1 and 14. 89Zr-J591 will be administered on day 21 (+ 1 day) and a
positron emission tomography-computed tomography (PET/CT) will be performed week later on day
28 + 1 (visit 4). Approximately 2 to 3 weeks after the 2nd dose of J591, the patient will
undergo radical prostatectomy with or without lymph node dissection (day 31 + 4 days). The
final visit for the study will include a postoperative visit two weeks following surgery.